Product Images Donepezil Hydrochloride

The text represents a table displaying the ADAS-cog change from baseline in mean (±SE) for different treatment options over weeks of drug treatment. The treatment options are Donepezil HCI 10mg/day, Donepezil HCI 5mg/day, and Placebo. The table also shows clinical improvement or decline based on the treatment option. Therefore, the text provides useful information to compare the efficacy of Donepezil HCI with the placebo over the selected time span.*

This is a graph displaying the cumulative percentage of patients' response to two different doses of Donepezil Hydrochloride (5 mg and 10 mg) in comparison to placebo. The patients' change in ADAS-cog score is also shown after 5 months of treatment at different dosage levels (0, 5, and 10 mg).*

This appears to be a table with three columns listing different medications and a row of ratings for each medication. The medications listed are "Donepezil HCI 10 mg/day", "Donepezil HCI 5 mg/day", and "Placebo". The ratings in the rows range from "Markedly Improved" to "Markedly Worse" with three additional levels in between. The row heading is "CIBIC-plus Rating". The purpose of the rating system and the context of the table are not given, so it is difficult to determine the significance of the information presented.*

This appears to be a poorly scanned document with some text being partially illegible due to blurring or other quality issues. The readable text seems to show some kind of medical study where participants were given a drug called Donepezil HCI at a dosage of 10 mg/day, and some participants received a placebo instead. The other text may be related to measurements or statistical data, but it is not clear enough to provide a useful description.*

This is a description of a medication called Donepezil Hydrochloride in tablet form with NDC code 69844-037-01. It contains 5mg of Donepezil Hydrochloride USP and the usual adult dosage can be found in the package insert. It is only available by prescription, and should be dispensed with a patient information leaflet in a tightly sealed, child-resistant container. The medication should be stored in a cool, dry place between 20-25°C (68°F to 77°F) with excursions permitted to 15-30°C (59°F to 86°F). This medication is manufactured by Graviti Pharmaceuticals Pvt, Ltd, in Telangana, India, and was packaged by Graviti Pharmaceuticals Inc., in Wilmington, Delaware, USA. The lot and expiration date are not available.*

This is a medication called Donepezil Hydrochloride available in the form of tablets with NDC number 69844-038-01. The tablets contain 10 mg of Donepezil Hydrochloride USP and are typically prescribed for adults. Patients should be given a patient information leaflet along with the medication. The recommended dosage and storage instructions are included, and it is manufactured by Graviti Pharmaceuticals Pyt. Ltd. in Telangana, India, and distributed by Graviti Pharmaceuticals Inc. in Wilmington, Delaware, USA. This text also includes the medication's lot number and expiration date.*